Exclusive Distribution of the OncAlert™ Oral Cancer Product Line in France, Algeria, Morocco and Tunisia

June 10, 2015
FORT LAUDERDALE, Florida

Vigilant Biosciences, Inc. (“Vigilant”), a leading innovator and developer of solutions that aid in the early detection and intervention of cancer, announced today that it has entered into a three-year exclusive sales and marketing agreement with Eurobio for the distribution of the OncAlert™ Oral Cancer product line in France, Algeria, Morocco and Tunisia. The OncAlert Oral Cancer product line includes the OncAlert Oral Cancer RAPID Test (“OncAlert RAPID Test”) and the OncAlert Oral Cancer LAB Test (“OncAlert LAB Test”).

Under the terms of the agreement, Eurobio will exclusively market and sell the OncAlert product line to the oral oncology markets in France, Algeria, Morocco and Tunisia pursuant to the CE Mark registration approvals of the products, which are expected by Q1 2016. Financial terms were not disclosed.

Headquartered in Les Ulis, France, Eurobio is a leading developer, manufacturer and marketer of high-quality, innovative in-vitro diagnostic products for biotechnology, research and pharmaceutical laboratories.

“We are pleased to announce the agreement with Eurobio for the sale of our OncAlert product line in France, Algeria, Morocco and Tunisia,” said Matthew H.J. Kim, Founder, Chairman, and CEO of Vigilant Biosciences, Inc. “Our distribution partners will be critical to our efforts to bring our oral cancer product line to the hundreds of thousands who suffer from oral cancer each year. Through our partnership with Eurobio, our goal is to provide innovative, effective and cost-effective products that will help aid in the earlier detection and intervention for patients.”

Based on 2012 incidence rate estimates by International Agency for Research on Cancer, there were more than 18,900 cases of head and neck cancer in France in 2012. Additionally, according to the World Health Organization and the HPV Information Centre, more than 38 million more people in France are at risk for oral cancer due to tobacco use, heavy drinking, or exposure to the HPV virus – key risk factors for the disease.

“We are excited to partner with Vigilant Biosciences to bring this important test to patients in France and North Africa,” said Jean-Michel Carle, CEO of Eurobio. “When healthcare professionals are armed with this system to quickly and accurately assess the risk of oral cancer, before it progresses to late stage, lives can be saved.”

About the OncAlert Oral Cancer Product Line
Vigilant Biosciences’ OncAlert RAPID Test and OncAlert LAB Test are the first and only technologies that measure soluble CD44 and total protein levels – protein markers clinically shown to be associated specifically with oral cancer when measured in an oral rinse – to aid clinicians in the early detection and intervention of oral cancer. Both products use a simple, oral rinse collection and measurement procedure that is easy to administer and non-invasive for the patient. The accurate, cost-effective tests can benefit every adult, with particular emphasis on high-risk populations (i.e., current and former tobacco users, those who consume excessive alcohol, and people with human papillomavirus). The OncAlert LAB Test is CE Marked. The OncAlert RAPID Test is currently undergoing the CE Mark registration process and not yet available for sale in any market at this time. The OncAlert Oral Cancer product line is not yet available for sale in the U.S.

About Oral Cancer
According to the Oral Cancer Foundation, there are over 640,000 new cases of oral cancer each year worldwide. In the U.S., close to 48,250 individuals will be diagnosed with oral or pharyngeal cancer this year, with 9,575 deaths from the disease, killing roughly one person per hour, 24 hours per day. Historically the death rate associated with this cancer is particularly high due to late-stage diagnosis and intervention. Currently, the vast majority of patients are detected through a visual exam and/or are symptomatic, at which point they are likely late stage. As a result, oral cancer often goes undetected to the point of metastasizing. Early diagnosis of oral cancer results in a cure rate of up to 90 percent.

About Eurobio
Founded in 1962, Eurobio is a leading developer, manufacturer and marketer of high-quality, innovative in-vitro diagnostic products for biotechnology, research and pharmaceutical laboratories. Eurobio works closely with scientists in research institutes including CNRS, INSERM, INRA, CNEVA, alongside life science companies, universities, hospitals and medical laboratories. Eurobio has two operating divisions: Life Sciences and Diagnostics managed by well-experienced staff. The company is located at Les Ulis, northwest of Paris. For more information, visit www.eurobio.fr.

About Vigilant Biosciences, Inc.
Vigilant Biosciences is a leading innovator and developer of solutions that aid in the early detection and intervention of cancer. Vigilant’s OncAlert Oral Cancer product line includes rapid and lab-based products that are simple, accurate and cost-effective, and empower healthcare practitioners to improve lives through earlier intervention. The OncAlert Oral Cancer product line is not yet available for sale in the U.S. For more information, visit www.vigilantbiosciences.com.

© 2020 Vigilant Biosciences

Follow Us

3900001 Rev2